GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019886 describes the biological process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its surface in association with an MHC class II protein complex.
• Exogenous antigens are internalized, processed in endosomal/lysosomal compartments, and loaded onto MHC class II molecules for presentation to CD4+ T cells.
• This pathway is essential for immune surveillance against pathogens and for maintaining tolerance; its dysregulation contributes to autoimmune diseases, immunodeficiency, and cancer immune evasion.
• Key molecular players include MHC class II heterodimers (HLA-DR, HLA-DQ, HLA-DP), invariant chain (CD74), HLA-DM, and cathepsins.
• Autophagy and cytoplasmic processing can intersect with the MHC class II pathway, broadening the repertoire of presented antigens.
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of this pathway in antigen-presenting cells.
Description
Antigen processing and presentation of exogenous peptide antigen via MHC class II (GO:0019886) is a central mechanism by which the adaptive immune system detects extracellular threats. In this process, specialized antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells internalize exogenous antigens, degrade them into peptides, and load these peptides onto MHC class II molecules for display on the cell surface. This pathway is distinct from MHC class I presentation, which primarily samples cytosolic antigens for CD8+ T cell recognition. The resulting peptide-MHC class II complexes are recognized by CD4+ T helper cells, which orchestrate downstream immune responses including antibody production, cytotoxic T cell activation, and cytokine release. Understanding GO:0019886 is therefore fundamental to immunology, vaccine design, and the pathogenesis of autoimmune and infectious diseases.
antigen processing and presentation of exogenous peptide antigen via MHC class II At A Glance
| GO ID | GO:0019886 |
|---|---|
| GO term | antigen processing and presentation of exogenous peptide antigen via MHC class II |
| Ontology | biological_process |
| Synonym | antigen presentation, exogenous antigen via MHC class II; antigen presentation, exogenous peptide antigen; antigen processing, exogenous antigen via major histocompatibility complex class II; exogenous peptide antigen processing and presentation via MHC class II |
| Major function | Uptake, processing, and presentation of exogenous antigens to CD4+ T cells |
| Cellular location | Endosomal/lysosomal compartments, plasma membrane |
| Key molecules | MHC class II (HLA-DR, HLA-DQ, HLA-DP), invariant chain (CD74), HLA-DM, cathepsins |
| Associated diseases | Autoimmune diseases, immunodeficiencies, cancer, infectious diseases |
What Is GO:0019886?
GO:0019886 is defined as the process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class II protein complex. The peptide antigen is typically, but not always, processed from a whole protein. This process encompasses antigen uptake, proteolytic processing in endosomal compartments, peptide loading onto MHC class II molecules, and surface presentation to CD4+ T cells.
Why Is antigen processing and presentation of exogenous peptide antigen via MHC class II Important in Cell Biology?
GO:0019886 is critical for initiating and shaping adaptive immune responses. It enables the immune system to detect extracellular pathogens and their products, and it is essential for the development of immunological memory. Defects in this pathway lead to severe immunodeficiency, while overactivation contributes to autoimmunity. Moreover, tumors often exploit this pathway to evade immune detection, making it a target for cancer immunotherapy.
• Enables CD4+ T cell activation and coordination of humoral and cellular immunity.
• Essential for host defense against bacterial, viral, and parasitic infections.
• Plays a role in central and peripheral tolerance, preventing autoimmunity.
• Dysregulation is linked to autoimmune diseases such as type 1 diabetes and multiple sclerosis.
• MHC class II expression levels on tumors correlate with prognosis and immunotherapy response.
• Vaccine efficacy often depends on efficient exogenous antigen presentation.
• Autophagy can deliver endogenous antigens to MHC class II, expanding the presented repertoire.
• Pathogens such as vaccinia virus encode inhibitors of MHC class II presentation.
• The pathway is a target for therapeutic modulation in allergy and transplantation.
• CRISPR screens have identified novel regulators of MHC class II antigen presentation.
What Happens During antigen processing and presentation of exogenous peptide antigen via MHC class II?
Antigen Uptake and Internalization
In simple terms: The cell engulfs material from outside.
Antigen-presenting cells capture exogenous antigens through phagocytosis, receptor-mediated endocytosis, or macropinocytosis. This step is critical for delivering antigens to endosomal compartments where processing occurs.
Proteolytic Processing in Endosomes/Lysosomes
In simple terms: Enzymes chop up the antigen into small pieces.
Internalized antigens are degraded by proteases such as cathepsins in increasingly acidic endosomal and lysosomal compartments. This generates peptides of appropriate length for MHC class II binding.
MHC Class II Synthesis and Invariant Chain Function
In simple terms: The MHC molecule is made and protected until it meets the peptide.
MHC class II alpha and beta chains are synthesized in the endoplasmic reticulum and associate with the invariant chain (CD74), which prevents premature peptide binding and directs the complex to endosomal compartments.
Peptide Loading and HLA-DM Catalysis
In simple terms: The peptide is inserted into the MHC molecule with help from a catalyst.
In late endosomes, the invariant chain is degraded, leaving a CLIP fragment in the MHC groove. HLA-DM catalyzes the exchange of CLIP for high-affinity exogenous peptides.
Surface Presentation to CD4+ T Cells
In simple terms: The loaded MHC molecule moves to the cell surface to show the peptide to T cells.
Peptide-MHC class II complexes are transported to the plasma membrane, where they are recognized by the T cell receptor of CD4+ T cells, leading to T cell activation and downstream immune responses.
Key Genes Involved in GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
The following genes encode proteins that are essential for the processing and presentation of exogenous antigens via MHC class II.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-DRA | MHC class II alpha chain | Antigen presentation; autoimmune disease associations |
| HLA-DRB1 | MHC class II beta chain | Most polymorphic; linked to rheumatoid arthritis, type 1 diabetes |
| HLA-DQA1 | MHC class II alpha chain | Celiac disease, narcolepsy |
| HLA-DQB1 | MHC class II beta chain | Celiac disease, type 1 diabetes |
| HLA-DPA1 | MHC class II alpha chain | Antigen presentation; transplantation |
| HLA-DPB1 | MHC class II beta chain | Transplantation, autoimmune risk |
| CD74 | Invariant chain; chaperone | Stabilizes MHC II; regulates peptide loading |
| HLA-DMA | HLA-DM alpha chain | Peptide editing; catalyzes CLIP exchange |
| HLA-DMB | HLA-DM beta chain | Peptide editing; essential for antigen presentation |
| CTSB | Cathepsin B; protease | Antigen processing; invariant chain degradation |
| CTSD | Cathepsin D; protease | Antigen processing in lysosomes |
| CTSL | Cathepsin L; protease | Invariant chain cleavage; antigen processing |
| LAMP1 | Lysosomal marker | Endosomal/lysosomal trafficking |
| LAMP2 | Lysosomal marker | Chaperone-mediated autophagy; antigen presentation |
| RAB7A | Late endosome trafficking | MHC class II transport |
| RAB5A | Early endosome trafficking | Antigen uptake and sorting |
| TAP1 | Peptide transporter | Cross-presentation; MHC I pathway |
| TAP2 | Peptide transporter | Cross-presentation; MHC I pathway |
How Is antigen processing and presentation of exogenous peptide antigen via MHC class II Regulated?
The MHC class II antigen presentation pathway is tightly regulated at multiple levels. Transcription of MHC class II genes is controlled by the master regulator CIITA (MHC2TA), which is induced by IFN-gamma. Post-translationally, invariant chain (CD74) and HLA-DM regulate peptide loading. Autophagy can modulate the delivery of endogenous antigens to MHC class II compartments. Additionally, pathogens such as vaccinia virus encode proteins that disrupt MHC class II-restricted antigen presentation.
antigen processing and presentation of exogenous peptide antigen via MHC class II and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-DRB1 | Rheumatoid arthritis, type 1 diabetes | Knock-in of risk alleles in mice or human cell lines |
| HLA-DQ2/DQ8 | Celiac disease | Overexpression in antigen-presenting cells |
| CD74 | Autoimmunity, cancer | Knockout in dendritic cells |
| HLA-DM | Immunodeficiency | Point mutation to abrogate catalytic activity |
| CTSL | Autoimmunity, cancer | Knockout in macrophages |
Autoimmune Diseases
Polymorphisms in MHC class II genes are strongly associated with autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and celiac disease. In type 1 diabetes, presentation of (pro)insulin peptides by MHC class II molecules triggers autoreactive CD4+ T cell responses. Similarly, in alopecia areata, collapse of hair follicle immune privilege involves MHC class II-mediated antigen presentation.
Cancer
Tumor cells often downregulate MHC class II expression to evade CD4+ T cell recognition. However, some tumors express MHC class II, which can be associated with better response to immunotherapy. Understanding the regulation of GO:0019886 in cancer cells is important for developing immunotherapies.
Infectious Diseases
Many pathogens have evolved mechanisms to subvert MHC class II antigen presentation. For example, vaccinia virus disrupts MHC class II-restricted antigen presentation, impairing CD4+ T cell activation. Conversely, efficient presentation is required for protective immunity against bacterial and viral infections.
From antigen processing and presentation of exogenous peptide antigen via MHC class II-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate MHC class II presentation? | CRISPR knockout in primary dendritic cells or cell lines |
| Does a disease-associated SNP in HLA-DR affect peptide binding? | Point mutation knock-in in HLA-DR-expressing cells |
| Can a tagged MHC class II molecule track trafficking? | Knock-in of fluorescent protein tag (e.g., GFP) at HLA-DRA locus |
| Does overexpression of CIITA enhance antigen presentation? | Overexpression of CIITA in tumor cells |
| Which genes are essential for exogenous antigen presentation? | Genome-wide CRISPR library screening |
| How does autophagy modulate MHC class II loading? | Knockout of ATG5 or ATG7 in APCs |
How to Study the antigen processing and presentation of exogenous peptide antigen via MHC class II Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface MHC class II levels | Quantify antigen presentation in APCs |
| Immunofluorescence | Subcellular localization of MHC II | Track endosomal trafficking |
| Mass spectrometry | MHC II-bound peptide repertoire | Identify immunopeptidome |
| CRISPR knockout screening | Genes required for presentation | Discover novel regulators |
| RNA-seq | Transcriptional changes | Assess CIITA and MHC II gene expression |
| Western blot | Protein levels of MHC II, CD74 | Validate knockout or overexpression |
| ELISPOT | Antigen-specific T cell activation | Functional readout of presentation |
| Proximity ligation assay | Protein-protein interactions | Detect MHC II-peptide complexes |
Flow Cytometry
Flow cytometry is used to measure surface expression of MHC class II and the efficiency of antigen presentation using fluorescently labeled antigens or specific antibodies.
Immunofluorescence Microscopy
Microscopy visualizes the intracellular trafficking of MHC class II and antigens through endosomal/lysosomal compartments, often using tagged proteins or specific markers.
Proteomics
Mass spectrometry-based proteomics identifies peptides eluted from MHC class II molecules, providing a snapshot of the presented immunopeptidome.
CRISPR Screening
Genome-wide CRISPR knockout screens coupled with MHC class II surface staining or antigen presentation readouts identify novel regulators of the pathway.
How CRISPR Can Be Used to Study GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
Knockout
CRISPR knockout of genes such as HLA-DRA, CD74, or CTSL in antigen-presenting cells abolishes or severely impairs exogenous antigen presentation, enabling functional studies.
Point Mutation
Point mutations can be introduced into HLA-DM or cathepsin active sites to dissect their catalytic roles in peptide loading and processing.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) at endogenous MHC class II loci allows real-time tracking of trafficking and presentation in live cells.
Overexpression
Overexpression of CIITA or specific MHC class II alleles in non-professional APCs can confer antigen-presenting capacity, useful for studying autoimmune mechanisms.
How EDITGENE Supports antigen processing and presentation of exogenous peptide antigen via MHC class II Research
Researchers studying antigen processing and presentation of exogenous peptide antigen via MHC class II-related genes often need to determine whether a candidate gene is causally involved in antigen uptake, processing, or presentation. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for antigen processing and presentation of exogenous peptide antigen via MHC class II research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| B2M Knockout A-549 Cell Line | EDC07863 | Human | 567 | Details Get a Quote |
| B2M Knockout HEK293T Cell Line | EDC07693 | Human | 567 | Details Get a Quote |
| B2M Knockout Hep-G2 Cell Line | EDJ-KQ38 | Human | 567 | Details Get a Quote |
| PIKFYVE Knockout SRA01/04 Cell Line | EDJ-KQ66 | Human | 200576 | Details Get a Quote |
| B2m Knockout C2C12 Cell Line | EDJ-KQ82 | Mouse | 12010 | Details Get a Quote |
| B2M Knockout K-562 Cell Line | EDJ-KQ85 | Human | 567 | Details Get a Quote |
| B2M Knockout SNU-449 Cell Line | EDJ-KQ89 | Human | 567 | Details Get a Quote |
| B2M Knockout THP-1 Cell Line | EDJ-KQ91 | Human | 567 | Details Get a Quote |
| PIKFYVE Knockout HEK293 Cell Line | EDJ-KQ1660 | Human | 200576 | Details Get a Quote |
| CTSF Knockout HEK293 Cell Line | EDJ-KQ2625 | Human | 8722 | Details Get a Quote |
| HLA-DRB4 Knockout HEK293 Cell Line | EDJ-KQ4081 | Human | 3126 | Details Get a Quote |
| CTSV Knockout HEK293 Cell Line | EDJ-KQ4384 | Human | 1515 | Details Get a Quote |
| CTSS Knockout HEK293 Cell Line | EDJ-KQ4387 | Human | 1520 | Details Get a Quote |
| HLA-DMA Knockout HEK293 Cell Line | EDJ-KQ4870 | Human | 3108 | Details Get a Quote |
| HLA-DOA Knockout HEK293 Cell Line | EDJ-KQ4871 | Human | 3111 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About antigen processing and presentation of exogenous peptide antigen via MHC class II
What is GO:0019886?
GO:0019886 is the Gene Ontology term for the biological process of antigen processing and presentation of exogenous peptide antigen via MHC class II, where antigen-presenting cells display exogenous peptides on MHC class II molecules to CD4+ T cells.
What genes are involved in antigen processing and presentation of exogenous peptide antigen via MHC class II?
Key genes include HLA-DRA, HLA-DRB1, HLA-DQA1, HLA-DQB1, CD74, HLA-DMA, HLA-DMB, CTSB, CTSD, and CTSL.
How does MHC class II present exogenous antigens?
Exogenous antigens are internalized, degraded in endosomes/lysosomes, and peptides are loaded onto MHC class II molecules with the help of HLA-DM, then presented on the cell surface.
What is the role of invariant chain in MHC class II presentation?
The invariant chain (CD74) binds to MHC class II in the endoplasmic reticulum, preventing premature peptide binding and guiding the complex to endosomal compartments.
What diseases are associated with defects in MHC class II antigen presentation?
Defects can cause immunodeficiency, while dysregulation is linked to autoimmune diseases like type 1 diabetes and rheumatoid arthritis, and cancer immune evasion.
How can CRISPR be used to study MHC class II antigen presentation?
CRISPR knockout, knock-in, and overexpression models allow precise manipulation of genes like HLA-DRA or CD74 to study their roles in antigen presentation.
What is the difference between MHC class I and MHC class II antigen presentation?
MHC class I presents endogenous peptides to CD8+ T cells, while MHC class II presents exogenous peptides to CD4+ T cells.
What experimental methods are used to study MHC class II antigen presentation?
Common methods include flow cytometry, immunofluorescence, mass spectrometry, and CRISPR screens.
Can autophagy influence MHC class II antigen presentation?
Yes, autophagy can deliver endogenous antigens to MHC class II compartments, expanding the repertoire of presented peptides.
How do pathogens evade MHC class II antigen presentation?
Some pathogens, like vaccinia virus, encode proteins that disrupt MHC class II-restricted antigen presentation, impairing CD4+ T cell activation.
Conclusion
GO:0019886 encompasses the essential biological process by which exogenous antigens are processed and presented via MHC class II molecules, a cornerstone of adaptive immunity. Its precise regulation is critical for host defense, tolerance, and immune homeostasis. Dysregulation underlies numerous diseases, from autoimmunity to cancer. Advanced CRISPR tools and multi-omics approaches continue to unravel the molecular details of this pathway, offering new therapeutic opportunities.
References
- 1. Bertolini M et al.. 2020. Hair follicle immune privilege and its collapse in alopecia areata.. Exp Dermatol 29(8):703-725 PMID: 32682334
- 2. Helft J et al.. 2015. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells.. Immunity 42(6):1197-211 PMID: 26084029
- 3. Wan Y et al.. 2005. Cross-presentation of phage particle antigen in MHC class II and endoplasmic reticulum marker-positive compartments.. Eur J Immunol 35(7):2041-50 PMID: 15940671
- 4. Zhou D et al.. 2004. Presentation of cytosolic antigens via MHC class II molecules.. Immunol Res 30(3):279-90 PMID: 15531770
- 5. Strawbridge AB et al.. 2007. Autophagy in MHC class II antigen processing.. Curr Opin Immunol 19(1):87-92 PMID: 17129719
- 6. Li P et al.. 2005. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing.. Immunol Rev 207:206-17 PMID: 16181338
- 7. Burster T et al.. 2010. Processing and presentation of (pro)-insulin in the MHC class II pathway: the generation of antigen-based immunomodulators in the context of type 1 diabetes mellitus.. Diabetes Metab Res Rev 26(4):227-38 PMID: 20503254
- 8. Li P et al.. 2005. Disruption of MHC class II-restricted antigen presentation by vaccinia virus.. J Immunol 175(10):6481-8 PMID: 16272302
